Evidence map›Paper›PMID 36673114›Full record

ReviewDiagnostics (Basel, Switzerland)2023

Role of Iron Deficiency in Heart Failure-Clinical and Treatment Approach: An Overview.

Cristina Elena Singer, Corina Maria Vasile, Mihaela Popescu, Alin Iulian Silviu Popescu, Iulia Cristina Marginean, George Alexandru Iacob, Mihai Daniel Popescu, Cristina Maria Marginean

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Diagnostics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
7.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Iron Deficiency as a Modifiable Risk Factor in Heart Failure: Evidence and Recommendations.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Iron Deficiency and its Relationship with Chronic Heart Failure- A Review.Cardiovascular & hematological agents in medicinal chemistry · 2025
    Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Cristina Elena SingerDepartment of Mother and Baby, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Corina Maria VasileDepartment of Pediatric and Adult Congenital Cardiology, Bordeaux University Hospital, 33600 Pessac, France.ORCID 0000-0002-4684-8213
Mihaela PopescuDepartment of Endocrinology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Alin Iulian Silviu PopescuDepartment of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Iulia Cristina MargineanFaculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
George Alexandru IacobFaculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Mihai Daniel PopescuFaculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Cristina Maria MargineanDepartment of Internal Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
University of Medicine and Pharmacy of Craiova · ROUniversité de Bordeaux · FR

Funding

University of Medicine and Pharmacy of Craiova, Romania 26/1031/8 October 2022
6 · The paper itself

Abstract

backgroundThe association of chronic heart failure (CHF) and iron deficiency (ID) with or without anemia is frequently encountered in current medical practice and has a negative prognostic impact, worsening patients' exercise capacity and increasing hospitalization costs. Moreover, anemia is common in patients with chronic kidney disease (CKD) and CHF, an association known as cardio-renal anemia syndrome (CRAS) possessing a significantly increased risk of death.

aimThis review aims to provide an illustrative survey on the impact of ID in CHF patients-based on physiopathological traits, clinical features, and the correlation between functional and absolute ID with CHF-and the benefit of iron supplementation in CHF.

methodWe selected the most recent publications with important scientific content covering the association of CHF and ID with or without anemia. DISCUSSIONS: An intricate physiopathological interplay is described in these patients-decrease in erythropoietin levels, activation of the renin-angiotensin-aldosterone system, systemic inflammation, and increases in hepcidin levels. These mechanisms amplify anemia, CHF, and CKD severity and worsen patients' outcomes.

conclusionsAnemia is frequently encountered in CHF and represents a negative prognostic factor. Data from randomized controlled trials have underlined the administration of intravenous iron therapy (ferric carboxymaltose) as the only viable treatment option, with beneficial effects on quality of life and exercise capacity in patients with ID and systolic heart failure.

Indexed as

chronic heart failurehemoglobiniron deficiency anemia

Identifiers

PMID36673114
PMCPMC9857585
OpenAlexW4316465774

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.